

NATIONAL AERONAUTICS AND SPACE ADMINISTRATION

[Notice (17-091)]

Notice of Intent To Grant Partially Exclusive Term License Take Out This Space**AGENCY:** National Aeronautics and Space Administration.**ACTION:** Notice of intent to grant partially exclusive term license.

SUMMARY: NASA hereby gives notice of its intent to grant a partially-exclusive term license in the United States to practice the invention described and claimed in U.S. Patent 6,760,487 entitled, "Estimated Spectrum Adaptive Postfilter And The Iterative Prepost Filtering Algorithms", and in U.S. Patent 9,414,072 entitled "Improved Performance of the JPEG Estimated Spectrum Adaptive Postfilter (JPEG-ESAP) for Low Bit Rates" to Human Health Organization ("H2O"), having its principal place of business in Studio City, CA.

DATES: The prospective partially-exclusive term license may be granted unless NASA receives written objections, including evidence and argument no later than January 18, 2018, that establish that the grant of the license would not be consistent with the requirements regarding the licensing of federally owned inventions as set forth in the Bayh-Dole Act and implementing regulations. Competing applications completed and received by NASA no later than January 18, 2018 will also be treated as objections to the grant of the contemplated partially exclusive license. Objections submitted in response to this notice will not be made available to the public for inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act.

ADDRESSES: Objections relating to the prospective license may be submitted to Patent Counsel, Bryan A. Geurts, Goddard Space Flight Center, 8800 Greenbelt Road, M/S 140.1, Greenbelt, MD 20771. Phone (301) 286-7351. Facsimile (301) 286-9502.

FOR FURTHER INFORMATION CONTACT: Enidia Santiago-Arce, Innovative Partnerships Program Office, Goddard Space Flight Center, 8800 Greenbelt Road, M/S 504, Greenbelt, MD 20771. Phone (301) 286-5810.

SUPPLEMENTARY INFORMATION: This notice of intent to grant a partially-exclusive term patent license is issued in accordance with 35 U.S.C. 209(e) and 37 CFR 404.7(a)(1)(i). The patent rights in these inventions have been assigned

to the United States of America as represented by the Administrator of the National Aeronautics and Space Administration. The prospective partially exclusive license will comply with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Information about other NASA inventions available for licensing can be found online at <http://technology.nasa.gov>.

Mark P. Dvorscak,*Agency Counsel for Intellectual Property.*

[FR Doc. 2017-28388 Filed 1-2-18; 8:45 am]

BILLING CODE 7510-13-P**NATIONAL TRANSPORTATION SAFETY BOARD****Sunshine Act Meeting****AGENDA****TIME AND DATE:** 9:00 a.m., Tuesday, January 23, 2018.**PLACE:** NTSB Conference Center, 429 L'Enfant Plaza SW, Washington, DC 20594.**STATUS:** The one item is open to the public.

MATTERS TO BE CONSIDERED: 5292 Aircraft Accident Report—Uncontained Engine Failure and Subsequent Fire, American Airlines Flight 383, Boeing 767-323, N345AN, Chicago, Illinois, October 28, 2016.

NEWS MEDIA CONTACT: Telephone: (202) 314-6100. The press and public may enter the NTSB Conference Center one hour prior to the meeting for set up and seating.

Individuals requesting specific accommodations should contact Rochelle McCallister at (202) 314-6305 or by email at Rochelle.McCallister@ntsb.gov by Wednesday, January 17, 2018.

The public may view the meeting via a live or archived webcast by accessing a link under "News & Events" on the NTSB home page at www.nts.gov.

Schedule updates, including weather-related cancellations, are also available at www.nts.gov.

FOR MORE INFORMATION CONTACT: Candi Bing at (202) 314-6403 or by email at bingc@ntsb.gov.

FOR MEDIA INFORMATION CONTACT: Peter Knudson at (202) 314-6100 or by email at peter.knudson@ntsb.gov.

Dated: December 29, 2017.

LaSean McCray,*Alternate Federal Register Liaison Officer.*

[FR Doc. 2017-28508 Filed 12-29-17; 4:15 pm]

BILLING CODE 7533-01-P**NUCLEAR REGULATORY COMMISSION**

[Docket No. 30-4675; NRC-2017-0221]

Department of Health and Human Services, Food and Drug Administration, Winchester Engineering and Analytical Center**AGENCY:** Nuclear Regulatory Commission.**ACTION:** License amendment application; opportunity to provide comments, request a hearing and to petition for leave to intervene.

SUMMARY: The U.S. Nuclear Regulatory Commission (NRC) has received a license amendment application from the Department of Health and Human Services, Food and Drug Administration (FDA) for the Winchester Engineering and Analytical Center located in Winchester, MA. The license authorizes the use of radioactive byproduct material for research and development. The licensee is requesting a partial site release for construction of a new 3-story building directly behind the existing main lab building.

DATES: Submit comments by February 2, 2018. Comments received after this date will be considered if it is practical to do so, but the Commission is able to ensure consideration only for comments received before this date. A request for a hearing or petition for leave to intervene must be filed by March 5, 2018.

ADDRESSES: You may submit comments by any of the following methods:

- *Federal Rulemaking website:* Go to <http://www.regulations.gov> and search for Docket ID NRC-2017-0221. Address questions about NRC dockets to Carol Gallagher; telephone: 301-415-3463; email: Carol.Gallagher@nrc.gov. For technical questions, contact the individual listed in the **FOR FURTHER INFORMATION CONTACT** section of this document.

- *Mail comments to:* May Ma, Office of Administration, Mail Stop: OWFN-2-A13, U.S. Nuclear Regulatory Commission, Washington, DC 20555-0001.

For additional direction on obtaining information and submitting comments, see "Obtaining Information and Submitting Comments" in the **SUPPLEMENTARY INFORMATION** section of this document.

FOR FURTHER INFORMATION CONTACT: Stephen Hammann, Division of Nuclear Materials Safety, Region I, U.S. Nuclear Regulatory Commission, 2100 Renaissance Boulevard, Suite 100, King of Prussia, Pennsylvania 19406;